ClinicalTrials.gg
CompletedNCT05955872Updated Sep 13, 2023

A Study Evaluating the Relative Bioavailability and Food Effect of a Tablet Formulation of VX-147

A Phase 1 interventional study of VX-147 in Focal Segmental Glomerulosclerosis (FSGS), sponsored by Vertex Pharmaceuticals Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-13.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States — 18 open to participants now, 21 under way, 2 of them phase 3. Glomerulosclerosis, Focal Segmental · United States.

Enrollment
32nd of 56
21 · median 30
Started
2023
with 4 others
Phase 1
8 of 69
none open now
Registered
60th of 69
by date
Lead sponsor
3 of 69
Vertex Pharmaceuticals Incorporated

Among the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, this one is the 32nd largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2023, is one of 8 in phase 1, and was the 60th registered.

Glomerulosclerosis, Focal Segmental

106 studies on the registry are indexed under Glomerulosclerosis, Focal Segmental; 34 are open to participants now.

Browse Glomerulosclerosis, Focal Segmental studies →

Open to participants now

18 of the 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Glomerulosclerosis, Focal Segmental studies recruiting now, 11 (35%) set no upper age limit and 13 (42%) stop at 75 or younger; 23 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Glomerulosclerosis, Focal Segmental with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Focal Segmental Glomerulosclerosis (FSGS)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m\^2), inclusive
  • A total body weight greater than 50 kg

Key Exclusion Criteria:

  • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Sequence A: VX-147

    Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.

    Drug: VX-147

  • Experimental
    Sequence B: VX-147

    Participants will receive VX-147 test tablet under fed condition in Treatment Period 1, then VX-147 test tablet under fasted condition in Treatment Period 2, and VX-147 reference tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.

    Drug: VX-147

  • Experimental
    Sequence C: VX-147

    Participants will receive VX-147 test tablet under fasted condition in Treatment Period 1, then VX-147 reference tablet under fasted condition in Treatment Period 2, and VX-147 test tablet under fed condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.

    Drug: VX-147

Interventions

  • DrugVX-147

    Tablets for oral administration.

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of VX-147 Test Compared to VX-147 Reference

    Time frame: From Day 1 up to Day 16

  2. Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-147 Test Compared to VX-147 Reference

    Time frame: From Day 1 up to Day 16

  3. Cmax of VX-147 Test Compared Under Fed Versus Fasted State

    Time frame: From Day 1 up to Day 16

  4. AUC(0-inf) of VX-147 Test Compared Under Fed Versus Fasted State

    Time frame: From Day 1 up to Day 16

Secondary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious AEs

    Time frame: From Day -1 up to Day 27

07

Study locations

1 site
  • ICON Salt Lake City
    Salt Lake City, Utah 84124, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2023 to primary completion in Sep 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2023
First posted
Jul 21, 2023
StartActual
Jul 19, 2023
Primary completionActual
Sep 2, 2023
CompletionActual
Sep 2, 2023
Last update
Sep 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05955872
Responsible party
Sponsor
First posted
Jul 21, 2023
Start date
Jul 19, 2023
Primary completion
Sep 2, 2023
Completion
Sep 2, 2023
Last update
Sep 13, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inaxaplin

Start the discussion